AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by stock analysts at Janney Montgomery Scott in a research note issued to investors on Monday.

AMAG has been the subject of several other reports. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, September 28th. Cowen and Company restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. Zacks Investment Research cut shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Morgan Stanley began coverage on shares of AMAG Pharmaceuticals in a research note on Friday, September 8th. They issued an “overweight” rating and a $26.00 price objective for the company. Finally, BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $26.92.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded up 2.88% during mid-day trading on Monday, hitting $16.05. 1,593,740 shares of the company’s stock traded hands. AMAG Pharmaceuticals has a 1-year low of $15.20 and a 1-year high of $36.83. The stock has a 50 day moving average price of $18.35 and a 200-day moving average price of $18.95. The stock’s market cap is $566.37 million.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm’s quarterly revenue was up 24.3% compared to the same quarter last year. During the same period last year, the firm posted $1.45 earnings per share. Equities research analysts anticipate that AMAG Pharmaceuticals will post ($1.38) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/23/amag-pharmaceuticals-inc-amag-rating-reiterated-by-janney-montgomery-scott.html.

Hedge funds have recently bought and sold shares of the business. Hikari Power Ltd increased its position in AMAG Pharmaceuticals by 75.0% during the 2nd quarter. Hikari Power Ltd now owns 70,000 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after buying an additional 30,000 shares during the period. Vanguard Group Inc. increased its position in shares of AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after purchasing an additional 176,832 shares during the period. Legal & General Group Plc increased its position in shares of AMAG Pharmaceuticals by 1.3% in the first quarter. Legal & General Group Plc now owns 61,371 shares of the specialty pharmaceutical company’s stock worth $1,384,000 after purchasing an additional 770 shares during the period. Sei Investments Co. increased its position in shares of AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after purchasing an additional 54 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of AMAG Pharmaceuticals by 45.6% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 158,600 shares of the specialty pharmaceutical company’s stock worth $3,576,000 after purchasing an additional 49,700 shares during the period.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.